<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39436146</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1600-0897</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>American journal of reproductive immunology (New York, N.Y. : 1989)</Title><ISOAbbreviation>Am J Reprod Immunol</ISOAbbreviation></Journal><ArticleTitle>Neonatal SARS-CoV-2 mRNA Vaccination Efficacy Is Influenced by Maternal Antibodies.</ArticleTitle><Pagination><StartPage>e70001</StartPage><MedlinePgn>e70001</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/aji.70001</ELocationID><Abstract><AbstractText Label="PROBLEM" NlmCategory="OBJECTIVE">Vaccination in pregnancy guards against infection. Maternal antibodies, however, can inhibit antibody production in neonates. We sought to determine the effects of maternal vaccination on neonatal immune response to a SARS-CoV-2 mRNA vaccine.</AbstractText><AbstractText Label="METHOD OF STUDY" NlmCategory="METHODS">We hypothesized that mRNA-lipid nanoparticles (LNP) vaccination allows for a de novo neonatal antibody response even in the presence of vertically transmitted maternal antibodies. Female mice were vaccinated with SARS-CoV-2 spike receptor binding domain (RBD) mRNA-LNPs. Mice were then bred, and 21-day-old pups were inoculated with the same mRNA-LNPs. Spike-specific IgG ELISAs were performed using mouse serum. A SARS-CoV-2 spike protein peptide library to perform peptide ELISAs characterized high affinity binding domains within the spike protein. Results were analyzed with one-way ANOVAs with Tukey's multiple comparisons tests.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to pups of unvaccinated dams, there were high levels of spike-specific IgG detected in the pups of vaccinated dams at 3 weeks of life (p &lt; 0.0001). After neonatal vaccination, pups of unvaccinated dams had higher spike-specific serum IgG than pups of vaccinated dams at 12 weeks of life (p &lt; 0.001). Antibody specificity to peptide moieties within spike RBD were similar when comparing a vaccinated dam to her pup at Week 3 of life, with different binding affinities observed in the pups by Week 15 of life.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Pre-existing maternal antibodies may partially blunt the initial neonatal antibody response to mRNA-LNPs vaccination. This vaccine strategy, however, does not prohibit the subsequent development of a broad range of RBD antibody specificities that may be protective.</AbstractText><CopyrightInformation>© 2024 The Author(s). American Journal of Reproductive Immunology published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schumer</LastName><ForeName>Amy</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1881-8794</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Vermont Medical Center, Burlington, Vermont, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonney</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Vermont Medical Center, Burlington, Vermont, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harby</LastName><ForeName>Ethan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biological Sciences, University of Vermont, Burlington, Vermont, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majumdar</LastName><ForeName>Devdoot</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Vermont Medical Center, Burlington, Vermont, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Electrical and Biomedical Engineering, University of Vermont Medical Center, Burlington, Vermont, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UVM Cancer Center, University of Vermont Medical Center, Burlington, Vermont, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30GM118228-05</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20RR021905</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Am J Reprod Immunol</MedlineTA><NlmUniqueID>8912860</NlmUniqueID><ISSNLinking>1046-7408</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000711949">Lipid Nanoparticles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="Y">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007112" MajorTopicYN="N">Immunity, Maternally-Acquired</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">mRNA vaccination</Keyword><Keyword MajorTopicYN="N">maternal antibodies</Keyword><Keyword MajorTopicYN="N">neonatal immunity</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword><Keyword MajorTopicYN="N">vertical transmission</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>16</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39436146</ArticleId><ArticleId IdType="doi">10.1111/aji.70001</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>World Health Organization. WHO Coronavirus (COVID‐19) Dashboard. World Health Organization, updated November 2, 2023, accessed November 6, 2023, https://covid19.who.int/.</Citation></Reference><Reference><Citation>D. J. Jamieson and S. A. Rasmussen, “An Update on COVID‐19 and Pregnancy,” American Journal of Obstetrics and Gynecology 226, no. 2 (2022): 177–186, https://doi.org/10.1016/j.ajog.2021.08.054.</Citation></Reference><Reference><Citation>L. D. Zambrano, S. Ellington, P. Strid, et al., “Update: Characteristics of Symptomatic Women of Reproductive Age With Laboratory‐Confirmed SARS‐CoV‐2 Infection by Pregnancy Status—United States, January 22‐October 3, 2020,” MMWR Morbidity and Mortality Weekly Report 69, no. 44 (2020): 1641–1647, https://doi.org/10.15585/mmwr.mm6944e3.</Citation></Reference><Reference><Citation>S. Q. Wei, M. Bilodeau‐Bertrand, S. Liu, and N. Auger, “The Impact of COVID‐19 on Pregnancy Outcomes: A Systematic Review and Meta‐Analysis,” CMAJ 193, no. 16 (2021): E540–E548, https://doi.org/10.1503/cmaj.202604.</Citation></Reference><Reference><Citation>T. D. Metz, R. G. Clifton, B. L. Hughes, et al., “Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID‐19),” Obstetrics and Gynecology 137, no. 4 (2021): 571–580, https://doi.org/10.1097/AOG.0000000000004339.</Citation></Reference><Reference><Citation>J. Villar, S. Ariff, R. B. Gunier, et al., “Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID‐19 Infection: The INTERCOVID Multinational Cohort Study,” JAMA Pediatrics 175, no. 8 (2021): 817–826, https://doi.org/10.1001/jamapediatrics.2021.1050.</Citation></Reference><Reference><Citation>American Academy of Pediatrics. Children and COVID‐19: State‐Level Data Report, American Academy of Pediatrics, updated May 16, 2023, accessed November 6, 2023, https://www.aap.org/en/pages/2019‐novel‐coronavirus‐covid‐19‐infections/children‐and‐covid‐19‐state‐level‐data‐report/#:~:text=Since%20the%20pandemic%20began%2C%20children,%25%20of%20the%20US%20population.</Citation></Reference><Reference><Citation>K. J. Marks, M. Whitaker, N. T. Agathis, et al., “Hospitalization of Infants and Children Aged 0–4 Years With Laboratory‐Confirmed COVID‐19 — COVID‐NET, 14 States, March 2020–February 2022,” MMWR Morbidity and Mortality Weekly Report 71 (2022): 429–436.</Citation></Reference><Reference><Citation>M. Horiya, M. Hisano, Y. Iwasaki, et al., “Efficacy of Double Vaccination With the 2009 Pandemic Influenza A (H1N1) Vaccine During Pregnancy,” Obstetrics and Gynecology 118, no. 4 (2011): 887–894, https://doi.org/10.1097/AOG.0b013e31822e5c02.</Citation></Reference><Reference><Citation>K. Zaman, E. Roy, S. E. Arifeen, et al., “Effectiveness of Maternal Influenza Immunization in Mothers and Infants,” New England Journal of Medicine 359, no. 15 (2008): 1555–1564.</Citation></Reference><Reference><Citation>R. N. Theiler, M. Wick, R. Mehta, A. L. Weaver, A. Virk, and M. Swift, “Pregnancy and Birth Outcomes After SARS‐CoV‐2 Vaccination in Pregnancy,” American Journal of Obstetrics &amp; Gynecology MFM 3, no. 6 (2021): 100467, https://doi.org/10.1016/j.ajogmf.2021.100467.</Citation></Reference><Reference><Citation>J. Morgan, J. Biggio, J. Martin, et al., “Maternal Outcomes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Infection in Vaccinated Compared With Unvaccinated Pregnant Patients,” Obstetrics &amp; Gynecology 139, no. 1 (2022): 107–109, https://doi.org/10.1097/AOG.0000000000004621.</Citation></Reference><Reference><Citation>B. Kampmann, S. A. Madhi, I. Munjal, et al., “Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants,” New England Journal of Medicine 388, no. 16 (2023): 1451–1464, https://doi.org/10.1056/NEJMoa2216480.</Citation></Reference><Reference><Citation>P. Cohen, H. Schneck, and E. Dubow, “Prenatal Multiple Immunization,” Journal of Pediatrics 38, no. 6 (1951): 696–704, https://doi.org/10.1016/s0022‐3476(51)80131‐8.</Citation></Reference><Reference><Citation>F. M. Munoz, N. H. Bond, M. Maccato, et al., “Safety and Immunogenicity of Tetanus Diphtheria and Acellular Pertussis (Tdap) Immunization During Pregnancy in Mothers and Infants: A Randomized Clinical Trial,” JAMA 311, no. 17 (2014): 1760–1769, https://doi.org/10.1001/jama.2014.3633.</Citation></Reference><Reference><Citation>“Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. Committee Opinion No. 718. American College of Obstetricians and Gynecologists,” Obstetrics and Gynecology 130 (2017): e153–e157.</Citation></Reference><Reference><Citation>“Influenza Vaccination During Pregnancy. ACOG Committee Opinion No. 732. American College of Obstetricians and Gynecologists,” Obstetrics and Gynecology 131 (2018): e109–e114.</Citation></Reference><Reference><Citation>A. A. Kevin, L. H. Brenna, E. R. Laura, and ACOG, Maternal Respiratory Syncytial Virus Vaccination. ACOG Practice Advisory, American College of Obstetricians and Gynecologists, updated December 11, 2023, accessed January 3, 2024.</Citation></Reference><Reference><Citation>J. A. Morgan, J. R. Biggio Jr, J. K. Martin, et al., “Pregnancy Outcomes in Patients After Completion of the mRNA Coronavirus Disease 2019 (COVID‐19) Vaccination Series Compared with Unvaccinated Patients,” Obstetrics and Gynecology 141, no. 3 (2023): 555–562, https://doi.org/10.1097/AOG.0000000000005072.</Citation></Reference><Reference><Citation>R. M. Simeone, L. D. Zambrano, N. B. Halasa, et al., “Effectiveness of Maternal mRNA COVID‐19 Vaccination During Pregnancy Against COVID‐19–Associated Hospitalizations in Infants Aged &lt;6 Months During SARS‐CoV‐2 Omicron Predominance — 20 States, March 9, 2022–May 31, 2023,” MMWR Morbidity and Mortality Weekly Report 72, no. 39 (2023): 1057–1064.</Citation></Reference><Reference><Citation>A. Saso and B. Kampmann, “Vaccine Responses in Newborns,” Seminars in Immunopathology 39, no. 6 (2017): 627–642.</Citation></Reference><Reference><Citation>M. PrabhuDas, B. Adkins, H. Gans, et al., “Challenges in Infant Immunity: Implications for Responses to Infection and Vaccines,” Nature Immunology 12 (2011): 189–194, https://doi‐org.ezproxy.uvm.edu/10.1038/ni0311‐189.</Citation></Reference><Reference><Citation>H. Yang, G. Luo, Y. Zeng, et al., “The Distinct Impact of Maternal Antibodies on the Immunogenicity of Live and Recombinant Rotavirus Vaccines,” Vaccine 37, no. 30 (2019): 4061–4067, https://doi.org/10.1016/j.vaccine.2019.05.086.</Citation></Reference><Reference><Citation>S. Becker‐Dreps, S. Vilchez, D. Velasquez, et al., “Rotavirus‐Specific IgG Antibodies From Mothers' Serum May Inhibit Infant Immune Responses to the Pentavalent Rotavirus Vaccine,” Pediatric Infectious Disease Journal 34, no. 1 (2015): 115–116, https://doi.org/10.1097/INF.0000000000000481.</Citation></Reference><Reference><Citation>M. Vono, C. S. Eberhardt, F. Auderset, et al., “Maternal Antibodies Inhibit Neonatal and Infant Responses to Vaccination by Shaping the Early‐Life B Cell Repertoire Within Germinal Centers,” Cell Reports 28, no. 7 (2019): 1773–1784.e5, https://doi.org/10.1016/j.celrep.2019.07.047.</Citation></Reference><Reference><Citation>K. E. Jensen, F. M. Davenport, and A. V. Hennessy, “Characterization of Influenza Antibodies by Serum Absorption,” Journal of Experimental Medicine 104, no. 2 (1956): 199–209, https://doi.org/10.1084/jem.104.2.199.</Citation></Reference><Reference><Citation>J. S. New, B. L. P. Dizon, C. F. Fucile, A. F. Rosenberg, J. F. Kearney, and R. G. King, “Neonatal Exposure to Commensal‐Bacteria‐Derived Antigens Directs Polysaccharide‐Specific B‐1 B Cell Repertoire Development,” Immunity 53, no. 1 (2020): 172–186.e6, https://doi.org/10.1016/j.immuni.2020.06.006.</Citation></Reference><Reference><Citation>E. Willis, N. Pardi, K. Parkhouse, et al., “Nucleoside‐Modified mRNA Vaccination Partially Overcomes Maternal Antibody Inhibition of De Novo Immune Responses in Mice,” Science Translational Medicine 12, no. 525 (2020): eaav5701, https://doi.org/10.1126/scitranslmed.aav5701.</Citation></Reference><Reference><Citation>L. R. Baden, H. M. El Sahly, B. Essink, et al., for the COVE Study Group, “Efficacy and Safety of the mRNA‐1273 SARS‐CoV‐2 Vaccine,” New England Journal of Medicine 384, no. 5 (2021): 403–416, https://doi.org/10.1056/NEJMoa2035389.</Citation></Reference><Reference><Citation>J. Sadoff, G. Gray, A. Vandebosch, et al., “Safety and Efficacy of Single‐Dose Ad26.COV2.S Vaccine Against Covid‐19,” New England Journal of Medicine 384, no. 23 (2021): 2187–2201, https://doi.org/10.1056/NEJMoa2101544.</Citation></Reference><Reference><Citation>F. P. Polack, S. J. Thomas, N. Kitchin, et al., for the C4591001 Clinical Trial Group, “Safety and Efficacy of the BNT162b2 mRNA Covid‐19 Vaccine,” New England Journal of Medicine 383, no. 27 (2020): 2603–2615, https://doi.org/10.1056/NEJMoa2034577.</Citation></Reference><Reference><Citation>B. Montoya, C. R. Melo‐Silva, L. Tang, et al., “mRNA‐LNP Vaccine‐Induced CD8+ T Cells Protect Mice From Lethal SARS‐CoV‐2 Infection in the Absence of Specific Antibodies,” Molecular Therapy 32, no. 6 (2024): 1790–1804, https://doi.org/10.1016/j.ymthe.2024.04.019.</Citation></Reference><Reference><Citation>B. Freeman, S. Lester, L. Mills, et al., “Validation of a SARS‐CoV‐2 Spike Protein ELISA for Use in Contact Investigations and Serosurveillance,” bioRxiv preprint posted online April 25, 2020, https://doi.org/10.1101/2020.04.24.057323.</Citation></Reference><Reference><Citation>C. Atyeo and G. Alter, “The Multifaceted Roles of Breast Milk Antibodies,” Cell 184, no. 6 (2021): 1486–1499, https://doi.org/10.1016/j.cell.2021.02.031.</Citation></Reference><Reference><Citation>National Center for Biotechnology Information, S Surface Glycoprotein [Severe Acute Respiratory Syndrome Coronavirus 2] (Bethesda, MD: National Center for Biotechnology Information, 2023), https://www.ncbi.nlm.nih.gov/gene/43740568.</Citation></Reference><Reference><Citation>American College of Obstetricians and Gynecologists, COVID‐19 Vaccination Considerations for Obstetric‐Gynecologic Care. ACOG Practice Advisory, American College of Obstetricians and Gynecologists, updated September 25, 2023, accessed September 17, 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>